

## Developers Call FDA Guidance on Suffixes a 'Direct Blow' to Biosimilars

March 8, 2019

**ATTORNEYS** 

Landmon, Chad

**PRACTICE AREAS** 

FDA

Kelly Davio

The Center for Biosimilars

Axinn partner Chad Landmon was quoted in *The Center for Biosimilars* article, "Developers Call FDA Guidance on Suffixes a 'Direct Blow' to Biosimilars."

Click here to access the article.